Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Alkermes Plc is a drug manufacturers-specialty & generic business based in the US. Alkermes shares (ALKS) are listed on the NASDAQ and all prices are listed in US Dollars. Alkermes employs 2,211 staff and has a trailing 12-month revenue of around $1.2 billion.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $22.32 |
|---|---|
| 52-week range | $21.24 - $33.00 |
| 50-day moving average | $26.29 |
| 200-day moving average | $26.30 |
| Wall St. target price | $31.20 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.38 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $22.32 from 2022-09-23
| 1 week (2022-09-16) | -4.49% |
|---|---|
| 1 month (2022-08-25) | -10.51% |
| 3 months (2022-06-24) | -24.87% |
| 6 months (2022-03-25) | -18.63% |
| 1 year (2021-09-23) | -30.05% |
|---|---|
| 2 years (2020-09-25) | 33.33% |
| 3 years (2019-09-25) | 12.05% |
| 5 years (2017-09-25) | 51.78 |
Valuing Alkermes stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alkermes's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Alkermes's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $803,000.
The EBITDA is a measure of a Alkermes's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.2 billion |
|---|---|
| Gross profit TTM | $976.4 million |
| Return on assets TTM | -2.51% |
| Return on equity TTM | -8.64% |
| Profit margin | -8.02% |
| Book value | $6.59 |
| Market capitalisation | $3.8 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Alkermes.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 28.83
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Alkermes's overall score of 28.83 (as at 12/31/2018) is nothing to write home about – landing it in it in the 53rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Alkermes is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 0.37/100
Alkermes's environmental score of 0.37 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Alkermes is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 17.49/100
Alkermes's social score of 17.49 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Alkermes is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 8.71/100
Alkermes's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Alkermes is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Alkermes scored a 1 out of 5 for controversy – the highest score possible, reflecting that Alkermes has managed to keep its nose clean.
Alkermes Plc was last rated for ESG on: 2019-01-01.
| Total ESG score | 28.83 |
|---|---|
| Total ESG percentile | 53.12 |
| Environmental score | 0.37 |
| Environmental score percentile | 1 |
| Social score | 17.49 |
| Social score percentile | 1 |
| Governance score | 8.71 |
| Governance score percentile | 1 |
| Level of controversy | 1 |
We're not expecting Alkermes to pay a dividend over the next 12 months.
Alkermes's shares were split on a 2:1 basis on 14 May 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Alkermes shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Alkermes shares which in turn could have impacted Alkermes's share price.
Over the last 12 months, Alkermes's shares have ranged in value from as little as $21.24 up to $33. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alkermes's is 0.6121. This would suggest that Alkermes's shares are less volatile than average (for this exchange).
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N. V. , Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.